ABT · News · 20261022N
Strategic Business Separation
ABBOTT LABORATORIES · 2026-10-22 · Importance 71 · Surprise 60 · Contradicted
Abbott plans to separate its global Nutrition business into an independent publicly traded company with approximately $8.5 billion in annual sales. The transaction is expected to be completed by the end of 2027 and will include the Similac, Ensure and PediaSure brands. Daniel Salvadori is expected to lead the new company, which Abbott says will have distinct investment requirements, customer bases and growth profiles from its other businesses.
Key facts
- The proposed company generates approximately $8.5 billion in annual sales. source
- Abbott expects the nutrition spinoff to be completed by the end of 2027. source
- Abbott Laboratories used its third-quarter 2026 earnings call to outline a major portfolio restructuring, announcing plans to separate its Nutrition business into an independent publicly traded company. source
- Daniel Salvadori will lead the independent business. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +17.9% | The proposed company generates approximately $8.5 billion in annual sales. |